Comparison 1. TRIFLUOPERAZINE versus PLACEBO.

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Global state: 1a. No substantial improvement (defined as slight improvement or worse) ‐ by time period	6	415	Risk Ratio (M‐H, Random, 95% CI)	0.79 [0.66, 0.94]
1.1 short term (0‐3 months)	3	95	Risk Ratio (M‐H, Random, 95% CI)	0.63 [0.50, 0.79]
1.2 medium term (+3 months‐1 year)	3	320	Risk Ratio (M‐H, Random, 95% CI)	0.92 [0.85, 1.00]
2 Global state: 1b. No substantial improvement (short term) ‐ by rater's role	1		Risk Ratio (M‐H, Random, 95% CI)	Subtotals only
2.1 doctor rated	1	27	Risk Ratio (M‐H, Random, 95% CI)	0.62 [0.38, 1.00]
2.2 nurse rated	1	27	Risk Ratio (M‐H, Random, 95% CI)	0.86 [0.67, 1.11]
3 Global state: 1c. No substantial improvement ‐ by dose of trifluoperazine	1		Risk Ratio (M‐H, Random, 95% CI)	Subtotals only
3.1 low dose (15mg/day)	1	240	Risk Ratio (M‐H, Random, 95% CI)	0.93 [0.88, 0.99]
3.2 high dose (80mg/day)	1	240	Risk Ratio (M‐H, Random, 95% CI)	0.94 [0.89, 0.99]
4 Global state: 2. Not discharged from hospital ‐ by dose of trifluoperazine	1		Risk Ratio (M‐H, Random, 95% CI)	Subtotals only
4.1 low dose (15mg/day)	1	240	Risk Ratio (M‐H, Random, 95% CI)	0.98 [0.96, 1.01]
4.2 high dose (80mg/day)	1	240	Risk Ratio (M‐H, Random, 95% CI)	0.98 [0.96, 1.01]
5 Global state: 3. Use of additional antipsychotics or sedatives	2	77	Risk Ratio (M‐H, Random, 95% CI)	1.07 [0.18, 6.31]
6 Mental state: Delusions and hallucinations by the end of the study	1	23	Risk Ratio (M‐H, Random, 95% CI)	0.44 [0.19, 0.99]
7 Behaviour: 1. No improvement (Wings Behaviour Rating Scale) ‐ by >8 weeks ‐ 6 months	1	40	Risk Ratio (M‐H, Random, 95% CI)	0.41 [0.25, 0.70]
8 Behaviour: 2. Agitation	1	52	Risk Ratio (M‐H, Fixed, 95% CI)	1.0 [0.28, 3.58]
9 Leaving the study early	7		Risk Ratio (M‐H, Random, 95% CI)	Subtotals only
9.1 any reason	7	280	Risk Ratio (M‐H, Random, 95% CI)	0.94 [0.59, 1.48]
9.2 due to adverse events	3	142	Risk Ratio (M‐H, Random, 95% CI)	1.12 [0.24, 5.11]
9.3 due to relapse or worsening	5	205	Risk Ratio (M‐H, Random, 95% CI)	0.90 [0.50, 1.62]
10 Adverse events: 1. At least one adverse effect	2	67	Risk Ratio (M‐H, Random, 95% CI)	1.40 [0.90, 2.18]
11 Adverse events: 2. Cardiovascular	2		Risk Ratio (M‐H, Random, 95% CI)	Subtotals only
11.1 ECG abnormalities ‐ minor	1	27	Risk Ratio (M‐H, Random, 95% CI)	1.86 [0.58, 5.94]
11.2 hypertension	1	40	Risk Ratio (M‐H, Random, 95% CI)	2.0 [0.20, 20.33]
12 Adverse events: 3. Extrapyramidal	5		Risk Ratio (M‐H, Random, 95% CI)	Subtotals only
12.1 non‐specific ‐ any movement disorder	2	79	Risk Ratio (M‐H, Random, 95% CI)	2.27 [1.19, 4.33]
12.2 non‐specific ‐ antiparkinson drugs needed	4	195	Risk Ratio (M‐H, Random, 95% CI)	5.06 [2.49, 10.27]
12.3 specific ‐ akathisia (motor restlessness)	1	40	Risk Ratio (M‐H, Random, 95% CI)	3.00 [0.13, 69.52]
12.4 specific ‐ dyskinesia	1	27	Risk Ratio (M‐H, Random, 95% CI)	3.71 [0.47, 29.06]
12.5 specific ‐ oculogyric crisis	1	27	Risk Ratio (M‐H, Random, 95% CI)	3.71 [0.47, 29.06]
12.6 specific ‐ rigidity	1	40	Risk Ratio (M‐H, Random, 95% CI)	9.00 [1.25, 64.59]
12.7 specific ‐ tremors	1	40	Risk Ratio (M‐H, Random, 95% CI)	0.33 [0.01, 7.72]
13 Adverse events: 4. Haematological	1		Risk Ratio (M‐H, Random, 95% CI)	Subtotals only
13.1 eosinophilia >5%	1	27	Risk Ratio (M‐H, Random, 95% CI)	1.86 [0.41, 8.49]
13.2 leukocytosis	1	27	Risk Ratio (M‐H, Random, 95% CI)	1.55 [0.46, 5.22]
13.3 urea nitrogen increase	1	27	Risk Ratio (M‐H, Random, 95% CI)	1.39 [0.28, 7.05]
14 Adverse events: 5. Neurological	1		Risk Ratio (M‐H, Random, 95% CI)	Subtotals only
14.1 convulsions	1	52	Risk Ratio (M‐H, Random, 95% CI)	0.5 [0.10, 2.50]
14.2 faintness	1	52	Risk Ratio (M‐H, Random, 95% CI)	0.67 [0.12, 3.67]
14.3 urinary incontinence	1	52	Risk Ratio (M‐H, Random, 95% CI)	1.0 [0.22, 4.50]
15 Adverse events: 6. Somnolesence	3		Risk Ratio (M‐H, Random, 95% CI)	Subtotals only
15.1 drowsiness	3	119	Risk Ratio (M‐H, Random, 95% CI)	2.94 [1.42, 6.10]
15.2 insomnia	2	67	Risk Ratio (M‐H, Random, 95% CI)	0.92 [0.07, 12.05]
16 Adverse events: 7. Weight	1		Risk Ratio (M‐H, Random, 95% CI)	Subtotals only
16.1 gain >10 lb	1	27	Risk Ratio (M‐H, Random, 95% CI)	1.24 [0.34, 4.51]
16.2 loss >10 lb	1	27	Risk Ratio (M‐H, Random, 95% CI)	2.17 [0.71, 6.66]
17 Adverse events: 8. Miscellaneous	3		Risk Ratio (M‐H, Random, 95% CI)	Subtotals only
17.1 anorexia	1	52	Risk Ratio (M‐H, Random, 95% CI)	0.8 [0.24, 2.65]
17.2 blurred vision	3	119	Risk Ratio (M‐H, Random, 95% CI)	1.72 [0.47, 6.26]
17.3 nausea	1	27	Risk Ratio (M‐H, Random, 95% CI)	1.39 [0.28, 7.05]
17.4 oedema ‐ face	1	52	Risk Ratio (M‐H, Random, 95% CI)	1.0 [0.22, 4.50]
17.5 rashes	3	119	Risk Ratio (M‐H, Random, 95% CI)	1.09 [0.30, 4.01]
17.6 swallowing ‐ difficulties	1	52	Risk Ratio (M‐H, Random, 95% CI)	1.0 [0.22, 4.50]